Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer

The PI3K/AKT pathway is frequently altered in advanced human prostate cancer mainly through the loss of functional PTEN, and presents as potential target for personalized therapy. Our aim was to determine the therapeutic potential of the pan-AKT inhibitor, AZD5363, in PTEN-deficient prostate cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: De Velasco, Marco A., Kura, Yurie, Yoshikawa, Kazuhiro, Nishio, Kazuto, Davies, Barry R., Uemura, Hirotsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941290/
https://www.ncbi.nlm.nih.gov/pubmed/26910118
http://dx.doi.org/10.18632/oncotarget.7557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941290/
https://www.ncbi.nlm.nih.gov/pubmed/26910118
http://dx.doi.org/10.18632/oncotarget.7557

Ejemplares similares